The Goldman Sachs Group Cuts Silence Therapeutics (NASDAQ:SLN) Price Target to $4.00

Silence Therapeutics (NASDAQ:SLN) had its target price lowered by stock analysts at The Goldman Sachs Group from $6.00 to $4.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “sell” rating on the stock. The Goldman Sachs Group’s price objective points to a potential downside of 4.76% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Wednesday, January 29th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.60.

Silence Therapeutics Trading Down 2.8 %

Shares of Silence Therapeutics stock opened at $4.20 on Tuesday. The business’s 50-day moving average price is $5.58 and its 200-day moving average price is $11.65. Silence Therapeutics has a 12 month low of $4.06 and a 12 month high of $27.72. The firm has a market capitalization of $125.71 million, a PE ratio of -2.68 and a beta of 1.05.

Hedge Funds Weigh In On Silence Therapeutics

Hedge funds have recently bought and sold shares of the business. Redmile Group LLC increased its stake in shares of Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after purchasing an additional 500,000 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after acquiring an additional 268,250 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Silence Therapeutics by 424.8% in the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock valued at $7,222,000 after acquiring an additional 849,676 shares in the last quarter. Eventide Asset Management LLC purchased a new position in shares of Silence Therapeutics in the third quarter valued at approximately $11,635,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after acquiring an additional 165,300 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.